ClinConnect ClinConnect Logo
Search / Trial NCT07031804

Expectation Effects on Emotional Processing

Launched by UNIVERSITÄTSKLINIKUM HAMBURG-EPPENDORF · Jun 12, 2025

Trial Information

Current as of August 22, 2025

Not yet recruiting

Keywords

Positive Expectation Treatment Expectation F Mri Emotional Processing Placebo

ClinConnect Summary

This study is exploring how our expectations and past experiences affect the way we process emotions. Researchers want to understand how thinking positively or believing in a treatment can actually change how we feel and recognize emotions in others, especially happy faces. To do this, healthy adults will take part in brain scans (fMRI) while completing tasks that involve identifying emotions on faces. The study compares times when participants are led to have positive expectations (like a placebo effect) with times when no specific expectations are set. The goal is to see how these positive expectations influence mood and brain activity related to emotions and thinking.

Adults aged 18 to 35 who are generally healthy, can safely have an MRI scan, and speak German may be eligible to join. Participants should have normal or corrected vision and must agree to the study by signing consent forms. People currently taking certain medications, pregnant or breastfeeding, or with certain health issues won’t qualify. During the study, participants will be asked to complete tasks inside an MRI machine while their brain activity is measured. It’s important that participants believe in the treatment during screening, as this belief is part of the study. The findings could help us better understand how our minds influence emotions and could guide new ways to treat mood disorders in the future.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Aged 18-35 years
  • MRI compatible
  • Medical information and signed declaration of consent
  • Normal or corrected to normal vision
  • German speaking
  • Exclusion Criteria:
  • No informed consent
  • Current intake of central nervous system active drugs
  • Under influence of alcohol
  • BDI score above 12
  • Significant acute somatic or neurological diseases
  • History of psychiatric or neurological disorders
  • Pregnancy/ breastfeeding
  • Acute nasal diseases or injuries
  • MR-specific exclusion criteria (claustrophobia, pacemaker, non-MR compatible metallic objects)
  • fMRI data with strong artefacts or excessive movement will be excluded from analysis
  • If a participant does not believe in the treatment on the screening day, they will not be included for the main study days
  • If a participant drops out after study day one, they will be excluded from the analysis

About Universitätsklinikum Hamburg Eppendorf

Universitätsklinikum Hamburg-Eppendorf (UKE) is a leading academic medical center in Germany, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, UKE integrates state-of-the-art facilities with a multidisciplinary approach, fostering collaboration among top-tier researchers, clinicians, and healthcare professionals. The institution is dedicated to improving patient outcomes by conducting rigorous scientific investigations that address critical health challenges, ultimately contributing to the development of novel therapies and enhancing medical knowledge.

Locations

Hamburg, , Germany

Patients applied

0 patients applied

Trial Officials

Stefanie Brassen, Prof. Dr.

Principal Investigator

Department of Systems Neuroscience, University Hospital Hamburg-Eppendorf, Hamburg, Germany

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported